ArticleTherapeutic advances in neurological disorders2021

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).

Helmut Butzkueven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.